PURPOSE: To evaluate the prognostic significance of six epigenetic biomarkers (AIM1, CDH1, KIF1A, MT1G, PAK3, and RBM6 promoter hypermethlation) in a homogeneous group of prostate cancer patients, following radical prostatectomy (RP). PATIENTS AND METHODS: Biomarker analyses were performed retrospectively on tumors from 95 prostate cancer patients all with a Gleason score of 3 + 4 = 7 and a minimum follow-up period of 8 years. Using Quantitative Methylation Specific PCR (QMSP), we analyzed the promoter region of six genes in primary prostate tumor tissues. Time to any progression was the primary endpoint and development of metastatic disease and/or death from prostate cancer was a secondary endpoint. The association of clinicopathological and biomolecular risk factors to recurrence was performed using the Log-rank test and Cox proportional hazards model for multivariate analysis. To identify independent prognostic factors, a stepwise selection method was used. RESULTS: At a median follow-up time of 10 years, 48 patients (50.5%) had evidence of recurrence: Biochemical/PSA relapse, metastases, or death from prostate cancer. In the final multivariate analysis for time to progression, the significant factors were: Older age, HR = 0.95 (95% CI: 0.91, 1.0) (P = 0.03), positive lymph nodes HR = 2.11 (95% CI: 1.05, 4.26) (P = 0.04), and decreased hypermethylation of AIM1 HR = 0.45 (95% CI: 0.2, 1.0) (P = 0.05). CONCLUSIONS: Methylation status of AIM1 in the prostate cancer specimen may predict for time to recurrence in Gleason 3 + 4 = 7 patients undergoing prostatectomy. These results should be validated in a larger and unselected cohort.
PURPOSE: To evaluate the prognostic significance of six epigenetic biomarkers (AIM1, CDH1, KIF1A, MT1G, PAK3, and RBM6 promoter hypermethlation) in a homogeneous group of prostate cancerpatients, following radical prostatectomy (RP). PATIENTS AND METHODS: Biomarker analyses were performed retrospectively on tumors from 95 prostate cancerpatients all with a Gleason score of 3 + 4 = 7 and a minimum follow-up period of 8 years. Using Quantitative Methylation Specific PCR (QMSP), we analyzed the promoter region of six genes in primary prostate tumor tissues. Time to any progression was the primary endpoint and development of metastatic disease and/or death from prostate cancer was a secondary endpoint. The association of clinicopathological and biomolecular risk factors to recurrence was performed using the Log-rank test and Cox proportional hazards model for multivariate analysis. To identify independent prognostic factors, a stepwise selection method was used. RESULTS: At a median follow-up time of 10 years, 48 patients (50.5%) had evidence of recurrence: Biochemical/PSA relapse, metastases, or death from prostate cancer. In the final multivariate analysis for time to progression, the significant factors were: Older age, HR = 0.95 (95% CI: 0.91, 1.0) (P = 0.03), positive lymph nodes HR = 2.11 (95% CI: 1.05, 4.26) (P = 0.04), and decreased hypermethylation of AIM1 HR = 0.45 (95% CI: 0.2, 1.0) (P = 0.05). CONCLUSIONS: Methylation status of AIM1 in the prostate cancer specimen may predict for time to recurrence in Gleason 3 + 4 = 7 patients undergoing prostatectomy. These results should be validated in a larger and unselected cohort.
Authors: Michael W Kattan; Shahrokh F Shariat; Ben Andrews; Kuichun Zhu; Eduardo Canto; Kazumasa Matsumoto; Masatoshi Muramoto; Peter T Scardino; Makoto Ohori; Thomas M Wheeler; Kevin M Slawin Journal: J Clin Oncol Date: 2003-08-11 Impact factor: 44.544
Authors: Deborah A Kuban; Howard D Thames; Larry B Levy; Eric M Horwitz; Patrick A Kupelian; Alvaro A Martinez; Jeff M Michalski; Thomas M Pisansky; Howard M Sandler; William U Shipley; Michael J Zelefsky; Anthony L Zietman Journal: Int J Radiat Oncol Biol Phys Date: 2003-11-15 Impact factor: 7.038
Authors: John E Sylvester; John C Blasko; Peter D Grimm; Robert Meier; Judith A Malmgren Journal: Int J Radiat Oncol Biol Phys Date: 2003-11-15 Impact factor: 7.038
Authors: Misop Han; Alan W Partin; Marianna Zahurak; Steven Piantadosi; Johnathan I Epstein; Patrick C Walsh Journal: J Urol Date: 2003-02 Impact factor: 7.450
Authors: Srinivasan Yegnasubramanian; Jeanne Kowalski; Mark L Gonzalgo; Marianna Zahurak; Steven Piantadosi; Patrick C Walsh; G Steven Bova; Angelo M De Marzo; William B Isaacs; William G Nelson Journal: Cancer Res Date: 2004-03-15 Impact factor: 12.701
Authors: Leonel Maldonado; Mariana Brait; Myriam Loyo; Lauren Sullenberger; Kevin Wang; Sarah B Peskoe; Eli Rosenbaum; Roslyn Howard; Antoun Toubaji; Roula Albadine; George J Netto; Mohammad O Hoque; Elizabeth A Platz; David Sidransky Journal: J Urol Date: 2014-04-21 Impact factor: 7.450
Authors: Michael C Haffner; David M Esopi; Alcides Chaux; Meltem Gürel; Susmita Ghosh; Ajay M Vaghasia; Harrison Tsai; Kunhwa Kim; Nicole Castagna; Hong Lam; Jessica Hicks; Nicolas Wyhs; Debika Biswal Shinohara; Paula J Hurley; Brian W Simons; Edward M Schaeffer; Tamara L Lotan; William B Isaacs; George J Netto; Angelo M De Marzo; William G Nelson; Steven S An; Srinivasan Yegnasubramanian Journal: Nat Commun Date: 2017-07-26 Impact factor: 14.919
Authors: Mariana Brait; Leonel Maldonado; Maartje G Noordhuis; Maartje Noordhuis; Shahnaz Begum; Myriam Loyo; Maria Luana Poeta; Alvaro Barbosa; Vito M Fazio; Roberto Angioli; Carla Rabitti; Luigi Marchionni; Pauline de Graeff; Ate G J van der Zee; G Bea A Wisman; David Sidransky; Mohammad O Hoque Journal: PLoS One Date: 2013-09-27 Impact factor: 3.240